Scholarlink

<p>This observational study assessed drug-related problems (DRPs) and their effect on patient-related outcomes (PROs) in 120 hospitalized epileptic patients. Antiseizure medications (ASM) administered included levetiracetam (98%), valproic acid (31%), carbamazepine (18.3%), and phenytoin (16%). Antibiotics such as ceftriaxone (64%), vancomycin (30%), meropenem (31%), and piperacillin-tazobactam (53%) were primarily used to treat hospital-acquired infections (HAIs) and status epilepticus. <i>Klebsiella pneumoniae</i> (17%) and <i>Streptococcus pneumoniae</i> (16%) were the main culprits causing HAIs. Ventilator-associated pneumonia (VAP), hospital-acquired pneumonia (HAP), catheter-associated urinary tract infections (CAUTI), Central line-associated bloodstream infections (CLABSI), fever, and sinusitis are the HAIs faced by 45% of the patients. PCNE classification V.9.1 was used for the evaluation of DRPs in hospitalized epileptic patients. DRPs are found to be involved in causing many serious problems in hospitalized epileptic patients; they not only cause drug-drug interactions (DDIs) but also affect the patient’s quality of life (QOL), morbidity, and mortality rate. This study was incredibly insightful in evaluating DRPs and numerous clinical scenarios that affect PROs. Irrational use of antibiotics and other narrow therapeutic drugs should be administered and prescribed carefully since they have an impact on patient QOL, extended hospital stay, expensive treatment, and mortality rates in developing low and middle-income countries.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A prospective observational study evaluating drug-related problems and their impact on patient-related outcomes in hospitalized epileptic patients

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月13日

查看全文
  • Muhammad Ali,
  • Muhammad Harris Shoaib,
  • Quratulain Khan,
  • Zeb-un-Nisa,
  • Asma Irshad,
  • Shoaib Nawaz

摘要

This observational study assessed drug-related problems (DRPs) and their effect on patient-related outcomes (PROs) in 120 hospitalized epileptic patients. Antiseizure medications (ASM) administered included levetiracetam (98%), valproic acid (31%), carbamazepine (18.3%), and phenytoin (16%). Antibiotics such as ceftriaxone (64%), vancomycin (30%), meropenem (31%), and piperacillin-tazobactam (53%) were primarily used to treat hospital-acquired infections (HAIs) and status epilepticus. Klebsiella pneumoniae (17%) and Streptococcus pneumoniae (16%) were the main culprits causing HAIs. Ventilator-associated pneumonia (VAP), hospital-acquired pneumonia (HAP), catheter-associated urinary tract infections (CAUTI), Central line-associated bloodstream infections (CLABSI), fever, and sinusitis are the HAIs faced by 45% of the patients. PCNE classification V.9.1 was used for the evaluation of DRPs in hospitalized epileptic patients. DRPs are found to be involved in causing many serious problems in hospitalized epileptic patients; they not only cause drug-drug interactions (DDIs) but also affect the patient’s quality of life (QOL), morbidity, and mortality rate. This study was incredibly insightful in evaluating DRPs and numerous clinical scenarios that affect PROs. Irrational use of antibiotics and other narrow therapeutic drugs should be administered and prescribed carefully since they have an impact on patient QOL, extended hospital stay, expensive treatment, and mortality rates in developing low and middle-income countries.